Original Article |
| |
Could myeloperoxidase be a biomarker or predictor for colorectal cancer?Gulcin Sahingoz Erdal, Ramazan Korkusuz, Nilgun Isiksacan, Murat Cikot, Pinar Atar, Nursel Kocamaz. Abstract | | | | Aim: Colorectal cancer (CRC) is the 4th most common cancer, and tumor tissue has a higher amount of myeloperoxidase (MPO)-positive cells than normal tissue. We aimed to compare the parameters of myeloid and lymphoid cells and MPO levels in the venous blood of patients diagnosed with CRC and healthy volunteers.
Materials and methods: The patient group in the study consisted of people who were diagnosed with CRC and had not yet received local or systemic treatment. The control group was selected from non-cancer patients. The enzyme-linked immunosorbent assay was used for the quantitative determination of MPO in serum.
Results: A total of 56 patients were included in this study. The mean MPO level of the patient group was significantly lower than that of the control group (3.59, 5.2 pg/mL, p=0.007). As a result of the receiver operating characteristics curve analysis, the cut-off point obtained for MPO was determined to be 3.66. There were significantly more CRC patients in the group with an MPO value of 3.66 and below (p=0.001; p
Key words: Colorectal cancer, myeloperoxidase, predictor
|
|
|
|